CASI Pharmaceuticals Receives Clinical Trial Application Approval From China's NMPA To Proceed With Phase 1/2 Study Of CID-103 In Immune Thrombocytopenia
CASI Pharmaceuticals Receives Clinical Trial Application Approval From China's NMPA To Proceed With Phase 1/2 Study Of CID-103 In Immune Thrombocytopenia
casi製藥獲中國國家藥品監督管理局批准臨床試驗申請，以推進CID-103在免疫性血小板減少症的1/2期研究
CASI Pharmaceuticals Receives Clinical Trial Application Approval From China's NMPA To Proceed With Phase 1/2 Study Of CID-103 In Immune Thrombocytopenia
casi製藥獲中國國家藥品監督管理局批准臨床試驗申請，以推進CID-103在免疫性血小板減少症的1/2期研究
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間